Small Molecule Receptors as Imaging Targets

  • Aviv Hagooly
  • Raffaella Rossin
  • Michael J. WelchEmail author
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 185/2)


The aberrant expression and function of certain receptors in tumours and other diseased tissues make them preferable targets for molecular imaging. PET and SPECT radionuclides can be used to label specific ligands with high affinity for the target receptors. The functional information obtained from imaging these receptors can be used to better understand the systems under investigation and for diagnostic and therapeutic applications. This review discusses some of the aspects of receptor imaging with small molecule tracers by PET and SPECT and reviews some of the tracers for the receptor imaging of tumours and brain, heart and lung disorders.


Positron Emission Tomography Positron Emission Tomography Imaging Positron Emission Tomography Tracer Sigma Receptor Ligand Small Molecule Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abi Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Anjilvel, S, Pidcock J, Guo NN, Lombardo I, Mann JJ, Van Heertum R, Foged C, Halldin C, Laruelle M (2000) Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11 C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20: 225–243PubMedGoogle Scholar
  2. Ali H, Rousseau J, van Lier JE (1994) Synthesis of (17α, 20E∕Z)Iodovinyl testosterone and 19-nortestosterone derivatives as potential radioligands for androgen and progesterone receptors. J Steroid Biochem Mol Biol 49:15–29PubMedGoogle Scholar
  3. Ali H, Rousseau J, Ahmed N, Guertin V, Hochberg RB, van Lier JE (2003a) Synthesis of the 7α-cyano-(17α, 20E∕Z)-[125I]iodovinyl-19-nortestosterones: potential radioligands for androgen and progesterone receptors. Steroids 68:1163–1171PubMedGoogle Scholar
  4. Ali H, Rousseau J, Paquette B, Dube C, Marko B, van Lier JE (2003b) Synthesis and biological properties of 7α-cyano derivatives of the (17α, 20E∕Z)-[125I]iodovinyl- and 16α-[125I]iodo-estradiols. Steroids 68:1189–1200PubMedGoogle Scholar
  5. Andree B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin C, Farde L (1998) Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. J Clin Psychopharmacol 18:317–323PubMedGoogle Scholar
  6. Anthonio RL, Brodde O-E, van Veldhuisen DJ, Scholtens E, Crijns HJGM, van Gilst WH (2000) β-Adrenoceptor density in chronic infarcted myocardium: a subtype specific decrease of β1-adrenoceptor density. Int J Cardiol 72:137–141PubMedGoogle Scholar
  7. Antoni G, Ulin J, Langstrom B (1989) Synthesis of the 11C-labelled β-adrenergic receptor ligands atenolol, metoprolol and propranolol. Appl Radiat Isot 40:561–564Google Scholar
  8. Antony AC (1996) Folate receptors. Annu Rev Nutr 16:501–521PubMedGoogle Scholar
  9. Arnett CD, Wolf AP, Shiue CY, Fowler JS, MacGregor RR, Christman DR, Smith MR (1986) Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET. J Nucl Med 27:1878–1882PubMedGoogle Scholar
  10. Arterburn JB, Corona C, Rao KV, Carlson KE, Katzenellenbogen JA (2003) Synthesis of 17-α-substituted estradiol-pyridin-2-yl hydrazine conjugates as effective ligands for labeling with Alberto’s complex fac-[Re(OH2)3(CO)3]+ in water. J Org Chem 68:7063–7070PubMedGoogle Scholar
  11. Asselin MC, Amano S, Chirakal R, Thompson M, Nahmias C (2002) Patterns of distribution of [18F]6-fluoro-L-m-tyrosine in PET images of patients with movement disorders. In: Senda M, Kimura Y, Herscovitch P (eds) Brain imaging with PET. Academic Press, San DiegoGoogle Scholar
  12. Baeken C, D’haenen H, Flamen P, Mertens J, Terriere D, Chavatte K, Boumon R, Bossuyt A (1998) 123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects. Eur J Nucl Med Mol Imaging 25:1617–1622Google Scholar
  13. Balle T, Halldin C, Andersen L, Hjorth Alifrangis L, Badolo L, Gjervig Jensen K, Chou Y-W, Andersen K, Perregaard J, Farde L (2004) New α1-adrenoceptor antagonists derived from the antipsychotic sertindole-carbon-11 labelling and pet examination of brain uptake in the cynomolgus monkey. Nucl Med Biol 31:327–336PubMedGoogle Scholar
  14. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123:2321–2337PubMedGoogle Scholar
  15. Barnes PJ (2004) Distribution of receptor targets in the lung. Proc Am Thorac Soc 1:345–351PubMedGoogle Scholar
  16. Barrio JR, Huang SC, Phelps ME (1997) Biological imaging and the molecular basis of dopaminergic diseases. Biochem Pharmacol 54:341–348PubMedGoogle Scholar
  17. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM, Aboagye EO (2003) 3-Deoxy-3-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63:3791–3798PubMedGoogle Scholar
  18. Beer HF, Blauenstein PA, Hasler PH, Delaloye B, Riccabona G, Banger I, Hunkeler W, Bonetti EP, Pieri L, Richards JG, Schubiger PA (1990) In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 31:1007–1014PubMedGoogle Scholar
  19. Bencherif B, Guarda AS, Colantuoni C, Ravert HT, Dannals RF, Frost JJ (2005) Regional μ-opioid receptor binding in insular cortex is decreased in bulimia nervosa and correlates inversely with fasting behavior. J Nucl Med 46:1349–1351PubMedGoogle Scholar
  20. Bennink RJ, Rijks LJ, van Tienhoven G, Noorduyn LA, Janssen AG, Sloof GW (2001) estrogen receptor status in primary breast cancer: iodine 123-labeled cis-11β-methoxy-17α-iodovinyl estradiol scintigraphy. Radiology 220:774–779PubMedGoogle Scholar
  21. Bennink RJ, van Tienhoven G, Rijks LJ, Noorduyn AL, Janssen AG, Sloof GW (2004) In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med 45:1–7PubMedGoogle Scholar
  22. Berardi F, Ferorelli S, Abate C, Colabufo NA, Contino M, Perrone R, Tortorella V (2004) 4-(Tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as σ receptor ligands with agonist σ2 activity. J Med Chem 47:2308–2317PubMedGoogle Scholar
  23. Berardi F, Ferorelli S, Abate C, Pedone MP, Colabufo NA, Contino M, Perrone R (2005) methyl substitution on the piperidine ring of N-[-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the σ1 receptor. J Med Chem 48:8237–8244PubMedGoogle Scholar
  24. Bettio A, Honer M, Muller C, Bruhlmeier M, Muller U, Schibli R, Groehn V, Schubiger AP, Ametamey SM (2006) Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. J Nucl Med 47:1153–1160PubMedGoogle Scholar
  25. Bigott HM, Parent E, Luyt LG, Katzenellenbogen JA, Welch MJ (2005) design and synthesis of functionalized cyclopentadienyl tricarbonylmetal complexes for technetium-94m PET imaging of estrogen receptors. Bioconjugate Chem 16:255–264Google Scholar
  26. Billings JJ, Kung M-P, Chumpradit S, Mozley D, Alavi A, Kung HF (1992) Characterization of radioiodinated TISCH: a high-affinity and selective ligand for mapping CNS D1 dopamine receptor. J Neurochem 58:227–236PubMedGoogle Scholar
  27. Blanckaert P, Burvenich I, Staelens L, Dierckx RA, Slegers G (2005) Synthesis, radiosynthesis and in vivo evaluation in mice of [123I]-(4-fluorophenyl) {1-[2-(4-iodophenyl)ethyl]piperidin-4-yl}methanone for visualization of the 5-HT2A receptor with SPECT. Appl Radiat Isot 62: 737–743PubMedGoogle Scholar
  28. Blin J, Sette G, Fiorelli M, Bletry O, Elghozi JL, Crouzel C, Baron JC (1990) A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. J Neurochem 54:1744–1754PubMedGoogle Scholar
  29. Boja JW, Patel A, Ivy Carroll F, Abdur Rahman M, Philip A, Lewin AH, Kopajtic TA, Kuhar MJ (1991) [125I]RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 194:133–134PubMedGoogle Scholar
  30. Bonasera TA, O’Neil JP, Xu M, Dobkin JA, Cutler PD, Lich LL, Choe YS, Katzenellenbogen JA, Welch MJ (1996) preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 37:1009–1015PubMedGoogle Scholar
  31. Bradley TC, Tanjore KN, Bingzhi S, Jogeshwar M (2000) Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [18F]fallypride in nonhuman primates. Synapse 38:71–79Google Scholar
  32. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P (1986) β1 and β2-adrenergic subpopulations in non-failing and failing human ventricle myocardium: coupling of both receptor subtypes to muscle contraction and selective β1 receptor downregulation in heart failure. Circ Res 59:297–309PubMedGoogle Scholar
  33. Bristow MR, Minobe W, Rasmussen R, Hershberger RE, Hoffman BB (1988) α1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther 247:1039–1045PubMedGoogle Scholar
  34. Brodde OE (1991) β1 and β2 adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43:203–242PubMedGoogle Scholar
  35. Burn DJ, O’Brien JT (2003) Use of functional imaging in Parkinsonism and dementia. Mov Disord 18:S88–S95PubMedGoogle Scholar
  36. Burns HD, Dannals RF, Langstrom B, Ravert HT, Zemyan SE, Duelfer T, Wong DF, Frost JJ, Kuhar MJ, Wagner HN Jr, (1984) (3-N-[11C]methyl)spiperone, a ligand binding to dopamine receptors: radiochemical synthesis and biodistribution studies in mice. J Nucl Med 25: 1222–1227PubMedGoogle Scholar
  37. Camargo EE (2001) Brain SPECT in neurology and psychiatry. J Nucl Med 42:611–623PubMedGoogle Scholar
  38. Camsonne R, Crouzel C, Comar D, Mazière M, Prenant C, Sastre J, Moulin M, Syrota A (1984) Synthesis of N-(11C) methyl, N-(methyl-1 propyl), (chloro-2 phenyl)-1 isoquinoleine carboxamide-3 (PK 11195): a new ligand for peripheral benzodiazepine receptors. J Labelled Comp Radiopharm 21:985–991Google Scholar
  39. Cappelli A, Matarrese M, Moresco RM, Valenti S, Anzini M, Vomero S, Turolla EA, Belloli S, Simonelli P, Filannino MA (2006) Synthesis, labeling, and biological evaluation of halogenated 2-quinolinecarboxamides as potential radioligands for the visualization of peripheral benzodiazepine receptors. Bioorg Med Chem 14:4055–4066PubMedGoogle Scholar
  40. Castellano M, Bohm M (1997) The cardiac β-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 29:715–722PubMedGoogle Scholar
  41. Catafau AM, Danus M, Bullich S, Nucci G, Llop J, Abanades S, Cunningham VJ, Eersels JLH, Pavia J, Farre M (2006) Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: part 2 – ketanserin displacement. J Nucl Med 47:929–937PubMedGoogle Scholar
  42. Caulfield MP, Birdsall NJM (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279–290PubMedGoogle Scholar
  43. Caveliers V, Everaert H, Lahoutte T, Dierickx LO, John CS, Bossuyt A (2001) Labelled sigma receptor ligands: can their role in neurology and oncology be extended? Eur J Med Chem 28:133–135Google Scholar
  44. Caveliers V, Everaert H, John CS, Lahoutte T, Bossuyt A (2002) Sigma receptor scintigraphy with N-[2-(1’-piperidinyl)ethyl]-3-123I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results. J Nucl Med 43:1647–1649PubMedGoogle Scholar
  45. Chang YS, Jeong JM, Yoon YH, Kang WJ, Lee SJ, Lee DS, Chung J–K, Lee MC (2005) Biological properties of 2-[18F]fluoroflumazenil for central benzodiazepine receptor imaging. Nucl Med Biol 32:263–268PubMedGoogle Scholar
  46. Choe YS, Katzenellenbogen JA (1995a) Synthesis of C-6 fluoroandrogens: evaluation of ligands for tumor receptor imaging. Steroids 60:414–422PubMedGoogle Scholar
  47. Choe YS, Lidstrom PJ, Chi DY, Bonasera TA, Welch MJ, Katzenellenbogen JA (1995b) Synthesis of 11 β-[18F]fluoro-5 α-dihydrotestosterone and 11 β-[18F]fluoro-19-nor-5 α-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution. J Med Chem 38:816–825PubMedGoogle Scholar
  48. Choi SR, Yang B, Plossl K, Chumpradit S, Wey SP, Acton PD, Wheeler K, Mach RH, Kung HF (2001) Development of a Tc-99m labeled σ2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol 28:657–666PubMedGoogle Scholar
  49. Choudhury L, Guzzetti S, Lefroy DC, Nihoyannopoulos P, McKenna WJ, Oakley CM, Camici PG (1996) Myocardial β adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart 75:50–54PubMedGoogle Scholar
  50. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55–61PubMedGoogle Scholar
  51. Clayson J, Jales A, Tyacke RJ, Hudson AL, Nutt DJ, Lewis JW, Husbands SM (2001) Selective δ–opioid receptor ligands:potential PET ligands based on naltrindole. Bioorg Med Chem Lett 11:939–943PubMedGoogle Scholar
  52. Coenen HH, Laufer P, Stocklin G, Wienhard K, Pawlik G, Bocher-Schwarz HG, Heiss WD (1987) 3-N-(2-[18F]-fluoroethyl)-spiperone: a novel ligand for cerebral dopamine receptor studies with pet. Life Sci 40:81–88PubMedGoogle Scholar
  53. Cohen RM, Carson RE, Sunderl T (2000) Opiate receptor avidity in the thalamus is sexually dimorphic in the elderly. Synapse 38:226–229PubMedGoogle Scholar
  54. Colabufo NA, Berardi F, Contino M, Fazio F, Matarrese M, Moresco RM, Niso M, Perrone R, Tortorella V (2005) Distribution of sigma receptors in EMT-6 cells: preliminary biological evaluation of PB167 and potential for in vivo PET. J Pharm Pharmacol 57:1453–1460PubMedGoogle Scholar
  55. Corr PB, Crafford WA (1981) Enhanced α–adrenergic responsiveness in ischemic myocardium: role of α-adrenergic blockade. Am Heart J 102:605–612PubMedGoogle Scholar
  56. Cropley VL, Fujita M, Musachio JL, Hong J, Ghose S, Sangare J, Nathan PJ, Pike VW, Innis RB (2006) Whole-body biodistribution and estimation of radiation-absorbed doses of the dopamine D1 receptor radioligand 11C-NNC 112 in humans. J Nucl Med 47:100–104PubMedGoogle Scholar
  57. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721–7735PubMedGoogle Scholar
  58. D’haenen H, Bossuyt A, Mertens J, Bossuyt–Piron C, Gijsemans M, Kaufman L (1992) SPECT imaging of serotonin 2 receptors in depression. Psychiatry Res 45:227–237PubMedGoogle Scholar
  59. DaSilva JN, Kilbourn MR (1992) In vivo binding of [11C]tetrabenazine to vesicular monoamine transporters in mouse brain. Life Sci 51:593–600PubMedGoogle Scholar
  60. DaSilva JN, Wilson AA, Nobrega JN, Jiwa D, Houle S (1996) Synthesis and autoradiographic localization of the dopamine D-1 agonists [11 C]SKF 75670 and [11C]SKF 82957 as potential PET radioligands. Appl Radiat Isot 47:279–284PubMedGoogle Scholar
  61. De Groot TJ, van Waarde A, Elsinga PH, Visser GM, Brodde OE, Vaalburg W (1993) Synthesis and evaluation of 1-[18F]fluorometoprolol as a potential tracer for the visualization of β-adrenoceptors with PET. Nucl Med Biol 20:637–642PubMedGoogle Scholar
  62. De Groot TJ, Braker AH, Elsinga PH, Visser GM, Vaalburg W (1994) Synthesis of 6 α-[18F]fluoroprogesterone: a first step towards a potential receptor-ligand for PET. Appl Radiat Isot 45:811–813PubMedGoogle Scholar
  63. De Jong RM, Willemsen AT, Slart RH, Blanksma PK, van Waarde A, Cornel JH, Vaalburg W, van Veldhuisen DJ, Elsinga PH (2005) Myocardial β-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388. Eur J Nucl Med Mol Imaging 32:443–447PubMedGoogle Scholar
  64. De La Fuente-Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, Ruth TJ, Stoessl AJ (2003) VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 49:20–28Google Scholar
  65. Dean B (2003) The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem 85:1–13PubMedGoogle Scholar
  66. Defraiteur C, Lemaire C, Luxen A, Plenevaux A (2006) Radiochemical synthesis and tissue distribution of p-[18F]DMPPF, a new 5 −HT1A ligand for PET, in rats. Nucl Med Biol 33:667–675PubMedGoogle Scholar
  67. Dehdashti F, McGuire AH, Van Brocklin HF, Siegel BA, Andriole DP, Griffeth LK, Pomper MG, Katzenellenbogen JA, Welch MJ (1991) Assessment of 21-[18F]fluoro-16 α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 32:1532–1537PubMedGoogle Scholar
  68. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ (1995) Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36:1766–1774PubMedGoogle Scholar
  69. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, Welch MJ (2005) Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32:344–350PubMedGoogle Scholar
  70. Delahaye N, Le Guludec D, Dinanian S, Delforge J, Slama MS, Sarda L, Dolle F, Mzabi H, Samuel D, Adams D, Syrota A, Merlet P (2001) Myocardial muscarinic receptor upregulation and normal response to isoproterenol in denervated hearts by familial amyloid polyneuropathy. Circulation 104:2911–2916PubMedGoogle Scholar
  71. Delforge J, Janier M, Syrota A, Crouzel C, Vallois JM, Cayla J, Lancon JP, Mazoyer BM (1990) Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. Circulation 82:1494–1504PubMedGoogle Scholar
  72. Dence CS, John CS, Bowen WD, Welch MJ (1997) Synthesis and evaluation of [18F] labeled benzamides: high affinity sigma receptor ligands for PET imaging. Nucl Med Biol 24: 333–340PubMedGoogle Scholar
  73. Denis LJ, Griffiths K (2000) Endocrine treatment in prostate cancer. Semin Surg Oncol 18:52–74PubMedGoogle Scholar
  74. Derry C, Benjamin C, Bladin P, le Bars D, Tochon-Danguy H, Berkovic SF, Zimmer L, Costes N, Mulligan R, Reutens D (2006) Increased serotonin receptor availability in human sleep:Evidence from an [18F]MPPF PET study in narcolepsy. Neuroimage 30:341–348PubMedGoogle Scholar
  75. Dixit V, VandenBossche J, Sherman DM, Thompson DH, Andres RP (2006) Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjugate Chem 17:603–609Google Scholar
  76. Doze P, Elsinga PH, van Waarde A, Pieterman RM, Pruim J, Vaalburg W, Willemsen AT (2002a) Quantification of β-adrenoceptor density in the human heart with (S)-[11C]CGP 12388 and a tracer kinetic model. Eur J Nucl Med Mol Imaging 29:295–304PubMedGoogle Scholar
  77. Doze P, van Waarde A, Tewson TJ, Vaalburg W, Elsinga PH (2002b) Synthesis and evaluation of (S)-[18F]-fluoroethylcarazolol for in vivo β-adrenoceptor imaging in the brain. Neurochem Int 41:17–27PubMedGoogle Scholar
  78. Drew GM (1976) Effects of α-adrenoceptor agonists and antagonists on pre- and postsynaptically located α-adrenoceptors. Eur J Pharmacol 36:313–320PubMedGoogle Scholar
  79. Drummond AE (2006) The role of steroids in follicular growth. Reprod Biol Endocrinol 10:4–16Google Scholar
  80. Eckelman WC (2006) Imaging of muscarinic receptors in the central nervous system. Curr Pharm Des 12:3901–3913PubMedGoogle Scholar
  81. Ehrin E, Luthra SK, Crouzel C, Pike VW (1988) Preparation of carbon-11 labelled prazosin, a potent and selective 1-adrenoreceptor antagonist. J Labelled Comp Radiopharm 25:177–183Google Scholar
  82. Elsinga PH, Van Waarde A, Visser GM, Vaalburg W (1994) Synthesis and preliminary evaluation of (R,S)-1-[2-((Carbamoyl-4-hydroxy)phenoxy)-ethylamino]-3-[4-(1-[11C]-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol ([11C]CGP 20712A) as a selective β1-adrenoceptor ligand for PET. Nucl Med Biol 21:211–217PubMedGoogle Scholar
  83. Elsinga PH, Vos MG, van Waarde A, Braker AH, de Groot TJ, Anthonio RL, Weemaes A-MA, Brodde O-E, Visser GM, Vaalburg W (1996) (S,S)- and (S,R)-1− [18F]fluorocarazolol, ligands for the visualization of pulmonary β-adrenergic receptors with PET. Nucl Med Biol 23: 159–167PubMedGoogle Scholar
  84. Elsinga PH, van Waarde A, Jaeggi KA, Schreiber G, Heldoorn M, Vaalburg W (1997) Synthesis and Evaluation of (S)-4-(3-(2− [11C]Isopropylamino)-2-hydroxypropoxy)-2H-benzimidazol-2-one ((S)-[11C]CGP 12388) and (S)-4 − (3 − ((1− [18F]Fluoroisopropyl)amino)-2-hydroxypropoxy)-2H-benzimidazol-2-one ((S)-[18F]Fluoro-CGP 12388) for visualization of β-adrenoceptors with positron emission tomography. J Med Chem 40:3829–3835PubMedGoogle Scholar
  85. Elsinga PH, van Waarde A, Vaalburg W (2004) Receptor imaging in the thorax with PET. Eur J Pharmacol 499:1–13PubMedGoogle Scholar
  86. Elsinga HP, Hatano K, Ishiwata K (2006) PET tracers for imaging of the dopaminergic system. Curr Med Chem 13:2139–2153PubMedGoogle Scholar
  87. Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, Litton JE, Sedvall G (1985) Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A 82:3863–3867PubMedGoogle Scholar
  88. Farde L, Halldin C, Stone-Elander S, Sedvall G (1987) PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl) 92:278–284Google Scholar
  89. Ferris CD, Hirsch DJ, Brooks BP, Snyder SH (1991) Sigma receptors: from molecule to man. J Neurochem 57:729–737PubMedGoogle Scholar
  90. Fischman AJ (2005) Role of [18F]-dopa-PET imaging in assessing movement disorders. Radiol Clin North Am 43:297–304Google Scholar
  91. Foged C, Halldin C, Loc’h C, Maziere B, Karlsson P, Maziere M, Swahn C-G, Farde L (1996) 11C- and 76Br-labelled NNC 22-0010, selective dopamine D1 receptor radioligands for PET. Nucl Med Biol 23:837–844PubMedGoogle Scholar
  92. Foged C, Halldin C, Loc’h C, Mazière B, Pauli S, Maziére M, Hansen HC, Suhara T, Swahn CG, Karlsson P, Farde L (1997) Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET). Eur J Nucl Med Mol Imaging 24:1261–1267Google Scholar
  93. Foged C, Halldin C, Swahn CG, Ginovart N, Karlsson P, Lundkvist C, Farde L (1998) [11C]NNC 22-0215, a metabolically stable dopamine D1 radioligand for PET. Nucl Med Biol 25:503–508PubMedGoogle Scholar
  94. Forbes JF (1997) The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24:S1-20–S21-35Google Scholar
  95. Forutan F, Estalji S, Beu M, Nikolaus S, Hamacher K, Coenen NN, Vosberg V (2002) Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem. Nuklearmedizin 41:197–201PubMedGoogle Scholar
  96. Frankle WG, Huang Y, Hwang D-R, Talbot PS, Slifstein M, Van Heertum R, Abi-Dargham A, Laruelle M (2004) Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 45:682–694PubMedGoogle Scholar
  97. Frost JJ, Wagner HN Jr, Dannals RF, Ravert HT, Links JM, Wilson AA, Burns HD, Wong DF, McPherson RW, Rosembaum AE, Kuhar MJ, Snyder SH (1985) Imaging opiate receptors in the human brain by positron emission tomography. J Comput Assist Tomogr 9:231–236PubMedGoogle Scholar
  98. Frost JJ, Smith AC, Kuhar MJ, Dannals RF, Wagner HN Jr (1987) In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci 40:987–995PubMedGoogle Scholar
  99. Fu X, Tan PZ, Kula NS, Baldessarini R, Tamagnan G, Innis RB, Baldwin RM (2002) Synthesis, Receptor Potency, and Selectivity of Halogenated Diphenylpiperidines as Serotonin 5-HT2A Ligands for PET or SPECT Brain Imaging. J Med Chem 45:2319–2324PubMedGoogle Scholar
  100. Furukawa T, Lohith TG, Takamatsu S, Mori T, Tanaka T, Fujibayashi Y (2006) Potential of the FES-hERL PET reporter gene system – Basic evaluation for gene therapy monitoring. Nucl Med Biol 33:145–151PubMedGoogle Scholar
  101. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177–1192PubMedGoogle Scholar
  102. Garg PK, Labaree DC, Hoyte RM, Hochberg RB (2001) 7α-[18F]fluoro-17α-methyl-5α-dihydrotestosterone: a ligand for androgen receptor-mediated imaging of prostate cancer. Nucl Med Biol 28:85–90PubMedGoogle Scholar
  103. Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305:137–138PubMedGoogle Scholar
  104. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB (2005) Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage 24:591–595PubMedGoogle Scholar
  105. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412PubMedGoogle Scholar
  106. Gibson RE, Weckstein DJ, Jagoda EM, Rzeszotarski WJ, Reba RC, Eckelman WC (1984) The characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro. J Nucl Med 25:214–222PubMedGoogle Scholar
  107. Giembycz MA, Newton R (2006) Beyond the dogma: novel β2-adrenoceptor signalling in the airways. Eur Respir J 27:1286–1306PubMedGoogle Scholar
  108. Göran S, Lars F, Allen B, Hakan H, Christer H (1991) 11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET. Psychopharmacology (Berl) 103:150–153Google Scholar
  109. Gosens R, Zaagsma J, Meurs H, Halayko AJ (2006) Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 7:73PubMedGoogle Scholar
  110. Goswami R, Ponde DE, Kung M-P, Hou C, Kilbourn MR, Kung HF (2006) Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 33:685–694PubMedGoogle Scholar
  111. Greenwald M, K., Johanson CE, Moody DE, Woods J, H., Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK (2003) Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000–2009PubMedGoogle Scholar
  112. Gründer G, Siessmeier T, Lange-Asschenfeldt C, Vernaleken I, Buchholz HG, Stoeter P, Drzezga A, Lüddens H, Rösch F, Bartenstein P (2001) [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur J Nucl Med Mol Imaging 28: 1463–147Google Scholar
  113. Guimaraes S, Moura D (2001) Vascular adrenoceptors: an update. Pharmacol Rev 53:319–356PubMedGoogle Scholar
  114. Guo W, Hinkle GH, Lee RJ (1999) 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 40:1563–1569PubMedGoogle Scholar
  115. Halldin C, Stone-Elander S, Farde L, Ehrin E, Fasth KJ, Langstrom B, Sedvall G (1986) Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum [A] 37:1039–1043Google Scholar
  116. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG (1995) Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36:1275–1281PubMedGoogle Scholar
  117. Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J, Sedvall G, Farde L (1998) Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med 39:2061–2068PubMedGoogle Scholar
  118. Harvey RD, Belevych AE (2003) Muscarinic regulation of cardiac ion channels. Br J Pharmacol 139:1074–1084PubMedGoogle Scholar
  119. Hashimoto K, Ishiwata K (2006) sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 12:3857–3876PubMedGoogle Scholar
  120. Heimbold I, Drews A, Syhre R, Kretzschmar M, Pietzsch H-J, Johannsen B (2002) A novel technetium-99m radioligand for the 5-HT1A receptor derived from desmethyl-WAY-100635 (DWAY). Eur J Nucl Med Mol Imaging 29:82–87PubMedGoogle Scholar
  121. Hein L (2006) Adrenoceptors and signal transduction in neurons. Cell Tissue Res 326:541–551PubMedGoogle Scholar
  122. Heinlein AC, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276–308PubMedGoogle Scholar
  123. Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, Dohmen BM, Braus DH, Schumann G, Machulla H-J, Bares R, Mann K (2005) Correlation of stable elevations in striatal μ-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62: 57–64PubMedGoogle Scholar
  124. Heiss WD, Herholz K (2006) Brain receptor imaging. J Nucl Med 47:302–312PubMedGoogle Scholar
  125. Henkel K, Karitzky J, Schmid M, Mader I, Glatting G, Unger JW, Neumaier B, Ludolph AC, Reske SN, Landwehrmeyer GB (2004) Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration. Mov Disord 19:817–821PubMedGoogle Scholar
  126. Henriksen G, Platzer S, Marton J, Hauser A, Berthele A, Schwaiger M, Marinelli L, Lavecchia A, Novellino E, Wester HJ (2005) Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as μ-opioid receptor imaging agents. J Med Chem 48: 7720–7732PubMedGoogle Scholar
  127. Hesse S, Barthel H, Schwarz J, Sabri O, Muller U (2004) Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci Biobehav Rev 28:547–563PubMedGoogle Scholar
  128. Heusch G (1990) α–Adrenergic mechanisms in myocardial ischemia. Circulation 81:1–13PubMedGoogle Scholar
  129. Hicks RJ, Kassiou M, Eu P, Katsifis AG, Garra M, Power J, Najdovski L, Lambrecht RM (1995) Iodine-123 N-methyl-4-iododexetimide:a new radioligand for single-photon emission tomographic imaging of myocardial muscarinic receptors. Eur J Nucl Med 22:339–345PubMedGoogle Scholar
  130. Hilgenbrink AR, Low PS (2005) Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94:2135–2146PubMedGoogle Scholar
  131. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SAW (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10:2751–2760PubMedGoogle Scholar
  132. Hostetler ED, Jonson SD, Welch MJ, Katzenellenbogen JA (1999) Synthesis of 2–[18F]fluoroestradiol, a potential diagnostic imaging agent for breast cancer: strategies to achieve nucleophilic substitution of an electron–rich aromatic ring with [18F]F. J Org Chem 64:178–185PubMedGoogle Scholar
  133. Hou C, Tu Z, Mach R, Kung HF, Kung M–P (2006) Characterization of a novel iodinated σ2 receptor ligand as a cell proliferation marker. Nucl Med Biol 33:203–209PubMedGoogle Scholar
  134. Houle S, DaSilva JN, Wilson AA (2000) Imaging the 5-HT1A receptors with PET: WAY-100635 and analogues. Nucl Med Biol 27:463–466PubMedGoogle Scholar
  135. Huang Y, Hammond PS, Whirrett BR, Kuhner RJ, Wu L, Childers SR, Mach RH (1998) synthesis and quantitative structure-activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective σ1 receptor ligands. J Med Chem 41:2361–2370PubMedGoogle Scholar
  136. Huang Y, Narendran R, Bae SA, Erritzoe D, Guo N, Zhu Z, Hwang DR, Laruelle M (2004) A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [11C]2-[2-dimethylaminomethylphenylthio)]-5-fluorophenylamine ([11C]AFA). Nucl Med Biol 31:727–738PubMedGoogle Scholar
  137. Hume SP, Ashworth S, Lammertsma AA, Opacka-Juffry J, Law MP, McCarron JA, Clark RD, Nutt DJ, Pike VW (1996) Evaluation in rat of RS-79948-197 as a potential PET ligand for central α2-adrenoceptors. Eur J Pharmacol 317:67–73PubMedGoogle Scholar
  138. Hume SP, Hirani E, Opacka-Juffry J, Osman S, Myers R, Gunn RN, McCarron JA, Clark RD, Melichar J, Nutt DJ, Pike VW (2000) Evaluation of [O-methyl-[11C]RS-15385-197 as a positron emission tomography radioligand for central α2-adrenoceptors. Eur J Nucl Med 27:475–484PubMedGoogle Scholar
  139. Hwang DR, Narendran R, Huang Y, Slifstein M, Talbot PS, Sudo Y, Van Berckel BN, Kegeles LS, Martinez D, Laruelle M (2004) Quantitative analysis of (–)-N-11C-propyl-norapomorphine in vivo binding in nonhuman primates. J Nucl Med 45:338–346PubMedGoogle Scholar
  140. Issa F, Kassiou M, Chan H, McLeod MD (2006) Synthesis and radiolabelling of ipratropium and tiotropium for use as pet ligands in the study of inhaled drug deposition. Aust J Chem 59:53–58Google Scholar
  141. Jacobson O, Bechor Y, Icar A, Novak N, Birman A, Marom H, Fadeeva L, Golan E, Leibovitch I, Gutman M (2005) Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives. Bioorg Med Chem 13:6195–6205PubMedGoogle Scholar
  142. Jacobson O, Laky D, Carlson KE, Elgavish S, Gozin M, Even-Sapir E, Leibovitc I, Gutman M, Chisin R, Katzenellenbogen JA, Mishani E (2006) Chiral dimethylamine flutamide derivatives–modeling, synthesis, androgen receptor affinities and carbon-11 labeling. Nucl Med Biol 33:695–704PubMedGoogle Scholar
  143. Jakobsen S, Pedersen K, Smith DF, Jensen SB, Munk OL, Cumming P (2006) Detection of α2-adrenergic receptors in brain of living pig with 11C-yohimbine. J Nucl Med 47:2008–2015PubMedGoogle Scholar
  144. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedGoogle Scholar
  145. Jewett DM, Kilbourn MR (2004) In vivo evaluation of new carfentanil-based radioligands for the μ-opiate receptor. Nucl Med Biol 31:321–325PubMedGoogle Scholar
  146. John CS, Vilner BJ, Gulden ME, Efange SM, Langason RB, Moody TW, Bowen WD (1995) Synthesis and pharmacological characterization of 4-[125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res 55:3022–3027PubMedGoogle Scholar
  147. John CS, Bowen WD, Fisher SJ, Lim BB, Geyer BC, Vilner BJ, Wahl RL (1999a) Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1-piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer. Nucl Med Biol 26:377–382PubMedGoogle Scholar
  148. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD (1999b) Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res 59:4578–4583PubMedGoogle Scholar
  149. Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M (1995) Changes in estrogen receptor, progesterone receptor, and ps2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55:3331–3338PubMedGoogle Scholar
  150. Jonson SD, Bonasera TA, Dehdashti F, Cristel ME, Katzenellenbogen JA, Welch MJ (1999) Comparative breast tumor imaging and comparative in vitro metabolism of 16α-[18F]fluoroestradiol-17β and 16β-[18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol 26:123–130PubMedGoogle Scholar
  151. Jutkiewicz EM (2006) The antidepressant -like effects of δ-opioid receptor agonists. Mol Interv 6:162–169PubMedGoogle Scholar
  152. Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrumsager B (1993) PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl) 113:149–156Google Scholar
  153. Karramkam M, Hinnen F, Berrehouma M, Hlavacek C, Vaufrey F, Halldin C, McCarron JA, Pike VW, Dolle F (2003) Synthesis of a [6-Pyridinyl-18F]-labelled fluoro derivative of WAY-100635 as a candidate radioligand for brain 5-HT1A receptor imaging with PET. Bioorg Med Chem 11:2769–2782PubMedGoogle Scholar
  154. Kassiou M, Scheffel U, Ravert HT, Mathews WB, Musachio JL, Lambrecht RM, Dannals RF (1995) [11C]A–69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. Nucl Med Biol 22:221–226PubMedGoogle Scholar
  155. Kassiou M, Mardon K, Mattner F, Katsifis A, Dikic B (2001) Pharmacological evaluation of (+)-2-[123I]A-69024 A radioligand for in vivo studies of dopamine D1 receptors. Life Sci 69:669–675PubMedGoogle Scholar
  156. Katchen B, Buxbaum S (1975) Disposition of a new, nonsteroid, antiandrogen α, α, α trifluoro 2 methyl 4 nitro m propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 41:373–379PubMedGoogle Scholar
  157. Katsifis A, Mardon K, Mattner F, Loc’h C, McPhee ME, Dikic B, Kassiou M, Ridley DD (2003) Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors. Nucl Med Biol 30:191–198PubMedGoogle Scholar
  158. Kawamura K, Elsinga PH, Kobayashi T, Ishii SI, Wang WF, Matsuno K, Vaalburg W, Ishiwata K (2003) Synthesis and evaluation of 11C- and 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol 30:273–284PubMedGoogle Scholar
  159. Kawamura K, Kubota K, Kobayashi T, Elsinga PH, Ono M, Maeda M, Ishiwata K (2005) Evaluation of [11C]SA5845 and [11C]SA4503 for imaging of sigma receptors in tumors by animal PET. Ann Nucl Med 19:701–709PubMedGoogle Scholar
  160. Ke CY, Mathias CJ, Yang Z–F, Luo J, Waters DJ, Low PS, Green MA (1999) Synthesis and evaluation of folate-bis(thiosemicarbazone) and folate-CYCLAM conjugates for possible use as folate-receptor-targeted copper radiopharmaceuticals. J Labelled Comp Radiopharm 42: S821–S823Google Scholar
  161. Ke CY, Mathias CJ, Green MA (2004) Folate-receptor-targeted radionuclide imaging agents. Adv Drug Deliv Rev 56:1143–1160PubMedGoogle Scholar
  162. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 60:1223–1229PubMedGoogle Scholar
  163. Kessler RM (2003) Imaging methods for evaluating brain function in man. Neurobiol Aging 24:S21–S35PubMedGoogle Scholar
  164. Kessler RM, Mason NS, Votaw JR, De Paulis T, Clanton JA, Ansari MS, Schmidt DE, Manning RG, Bell RL (1992) Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 223:105–107PubMedGoogle Scholar
  165. Khamssi M, Brodde OE (1990) The role of cardiac β1- and β2-adrenoceptor stimulation in heart failure. J Cardiovasc Pharmacol 16:S133–S137PubMedGoogle Scholar
  166. Kies P, Wichter T, Schafers M, Paul M, Schafers KP, Eckardt L, Stegger L, Schulze–Bahr E, Rimoldi O, Breithardt G, Schober O, Camici PG (2004) abnormal myocardial presynaptic norepinephrine recycling in patients with brugada syndrome. Circulation 110:3017–3022PubMedGoogle Scholar
  167. Kopka K, Wagner S, Riemann B, Law MP, Puke C, Luthra SK, Pike VW, Wichter T, Schmitz W, Schober O, Schafers M (2003) Design of new β1-selective adrenoceptor ligands as potential radioligands for in vivo imaging. Bioorg Med Chem 11:3513–3527PubMedGoogle Scholar
  168. Kopka K, Law MP, Breyholz HJ, Faust A, Holtke C, Riemann B, Schober O, Schafers M, Wagner S (2005) Non-invasive molecular imaging of β-adrenoceptors in vivo:perspectives for PET-radioligands. Curr Med Chem 12:2057–2074PubMedGoogle Scholar
  169. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93:5925–5930PubMedGoogle Scholar
  170. Kumar JSD, Majo VJ, Hsiung SC, Millak MS, Liu KP, Tamir H, Prabhakaran J, Simpson NR, VanHeertum RL, Mann JJ, Parsey RV (2006) Synthesis and in vivo validation of [o-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]butyl}-4-methyl-2h-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand. J Med Chem 49:125–134PubMedGoogle Scholar
  171. Kung HF (2001) Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent. Nucl Med Biol 28:505–508PubMedGoogle Scholar
  172. Kung HF, Guo YZ, Billings J, Xu X, Mach RH, Blau M, Ackerhalt RE (1988) Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. Int J Rad Appl Instrum B 15:195–201PubMedGoogle Scholar
  173. Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J, Alavi A (1989) In vitro and in vivo evaluation of [123I]IBZM:a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 30:88–92PubMedGoogle Scholar
  174. Kung HF, Frederick D, Kim HJ, McElgin W, Kung MP, Mu M, Mozley DP, Vessotskie JM, Stevenson AD, Kushner SA, Zhuang ZP (1996) In vivo SPECT imaging of 5-HT1A receptors with [123I] p-MPPI in nonhuman primates. Synapse 24:273–281PubMedGoogle Scholar
  175. Kung HF, Kung MP, Choi SR (2003) Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med 33:2–13PubMedGoogle Scholar
  176. Labaree DC, Brown TJ, Hoyte RM, Hochberg RB (1997) 7α-iodine-125-iodo-5α-dihydrotestosterone: a radiolabeled ligand for the androgen receptor. J Nucl Med 38:402–409PubMedGoogle Scholar
  177. Labaree DC, Hoyte RM, Nazareth LV, Weigel NL, Hochberg RB (1999) 7α-Iodo and 7α-fluoro steroids as androgen receptor-mediated imaging agents. J Med Chem 42:2021–2034PubMedGoogle Scholar
  178. Landel CC, Potthoff SJ, Nardulli AM, Kushner PJ, Greene GL (1997) Estrogen receptor accessory proteins augment receptor–DNA interaction and DNA bending. J Steroid Biochem Mol Biol 63:59–73PubMedGoogle Scholar
  179. Langer O, Halldin C, Dolle F, Swahn CG, Olsson H, Karlsson P, Hall H, Sandell J, Lundkvist C, Vaufrey F, Loc’h C, Crouzel C, Maziere B, Farde L (1999) Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors. Nucl Med Biol 26:509–518PubMedGoogle Scholar
  180. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H (2004) Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45:366–373PubMedGoogle Scholar
  181. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423–451PubMedGoogle Scholar
  182. Law MP, Osman S, Pike VW, Davenport RJ, Cunningham VJ, Rimoldi O, Rhodes CG, Giardinà D, Camici PG (2000) Evaluation of [11C]GB67, a novel radioligand for imaging myocardial α1-adrenoceptors with positron emission tomography. Eur J Nucl Med 27:7–17PubMedGoogle Scholar
  183. Le Guludec D, Delforge J, Syrota A, Desruennes M, Valette H, Gandjbakhch I, Merlet P (1994) In vivo quantification of myocardial muscarinic receptors in heart transplant patients. Circulation 90:172–178PubMedGoogle Scholar
  184. Le Guludec D, Cohen-Solal A, Delforge J, Delahaye N, Syrota A, Merlet P (1997) increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: an in vivo PET study. Circulation 96:3416–3422PubMedGoogle Scholar
  185. Leamon CP, Low PS (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 88:5572–5576PubMedGoogle Scholar
  186. Leamon CP, Reddy JA (2004) Folate-targeted chemotherapy. Adv Drug Deliv Rev 56:1127–1141PubMedGoogle Scholar
  187. Leamon CP, Parker MA, Vlahov IR, Xu LC, Reddy JA, Vetzel M, Douglas N (2002) synthesis and biological evaluation of EC20: a new folate-derived, 99 mTc-based radiopharmaceutical. Bioconjugate Chem 13:1200–1210Google Scholar
  188. Lefroy DC, De Silva R, Choudhury L, Uren NG, Crake T, Rhodes CG, Lammertsma AA, Boyd H, Patsalos PN, Nihoyannopoulos P, Oakley CM, Jones T, Camici PG (1993) Diffuse reduction of myocardial β-adrenoceptors in hypertrophic cardiomyopathy:a study with positron emission tomography. J Am Coll Cardiol 22:1653–1660PubMedGoogle Scholar
  189. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L (1991) Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 32:2266–2272PubMedGoogle Scholar
  190. Leon A, Rey A, Mallo L, Pirmettis I, Papadopoulos M, Leon E, Pagano M, Manta E, Incerti M, Raptopoulou C (2002) Novel mixed ligand technetium complexes as 5-HT1A receptor imaging agents. Nucl Med Biol 29:217–226PubMedGoogle Scholar
  191. Lever JR, Scheffel UA, Stathis M, Musachio JL, Wagner HN Jr (1990) In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors. Life Sci 46:1967–1976PubMedGoogle Scholar
  192. Li Q, Ma L, Innis RB, Seneca N, Ichise M, Huang H, Laruelle M, Murphy DL (2004) Pharmacological and genetic characterization of two selective serotonin transporter ligands: 2-[2-(dimethylaminomethylphenylthio)]-5–fluoromethylphenylamine (AFM) and 3-amino-4-[2-(dimethylaminomethyl-phenylthio)]benzonitrile (DASB). J Pharmacol Exp Ther 308: 481–486PubMedGoogle Scholar
  193. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA (2006) quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24:2793–2799PubMedGoogle Scholar
  194. Lingford HA (2005) Human brain imaging and substance abuse. Curr Opin Pharmacol 5:42–46Google Scholar
  195. Liu A, Dence CS, Welch MJ, Katzenellenbogen JA (1992) Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 33:724–734PubMedGoogle Scholar
  196. Liu AJ, Katzenellenbogen JA, VanBrocklin HF, Mathias CJ, Welch MJ (1991) 20-[18F]fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies. J Nucl Med 32:81–88PubMedGoogle Scholar
  197. Liu M, Xu W, Xu Lj, Zhong Gr, Chen Sl, Lu Wy (2005) Synthesis and biological evaluation of diethylenetriamine pentaacetic acid-polyethylene glycol-folate: a new folate-derived, 99 mTc-based radiopharmaceutical. Bioconjugate Chem 16:1126–1132Google Scholar
  198. Loc’h C, Halldin C, Bottlaender M, Swahn C-G, Moresco R–M, Maziere M, Farde L, Maziere B (1996) Preparation of [76Br]FLB 457 and [76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET. Nucl Med Biol 23:813–819Google Scholar
  199. Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn C-G, Carr AA, Brunner F, Farde L (1996) [11C]MDL 100907, a radioligand for selective imaging of 5-HT2A receptors with positron emission tomography. Life Sci 58:187–192Google Scholar
  200. Luo H, Hasan A, Sood V, McRee RC, Zeeberg B, Reba RC, McPherson DW, Knapp FF (1996) Evaluation of 1-azabicyclo[2.2.2]oct-3-yl α-fluoroalkyl-α-hydroxy-α-phenylacetates as potential ligands for the study of muscarinic receptor density by positron emission tomography. Nucl Med Biol 23:267–276PubMedGoogle Scholar
  201. Luyt LG, Bigott HM, Welch MJ, Katzenellenbogen JA (2003) 7α- and 17α-substituted estrogens containing tridentate tricarbonyl rhenium/technetium complexes: synthesis of estrogen receptor imaging agents and evaluation using microPET with technetium-94 m. Bioorg Med Chem 11:4977–4989PubMedGoogle Scholar
  202. Mach RH, Huang Y, Buchheimer N, Kuhner R, Wu L, Morton TE, Wang LM, Ehrenkaufer RL, Wallen CA, Wheeler KT (2001) [18F]N-4-Fluorobenzyl-4-(3–bromophenyl) acetamide for imaging the sigma receptor status of tumors:comparison with [18F]FDG and [125I]IUDR. Nucl Med Biol 28:451–458PubMedGoogle Scholar
  203. Machulla H-J, Heinz A (2005) Radioligands for brain imaging of the κ-opioid system. J Nucl Med 46:386–387PubMedGoogle Scholar
  204. Mankoff DA, Dehdashti F, Shields AF (2000) Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2:71–88PubMedGoogle Scholar
  205. Marek K, Jennings D, Seibyl J (2003) Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa. Neurology 61:S43–S48PubMedGoogle Scholar
  206. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532PubMedGoogle Scholar
  207. Matarrese M, Moresco RM, Romeo G, Turolla EA, Simonelli P, Todde S, Belloli S, Carpinelli A, Magni F, Russo F, Galli Kienle M, Fazio F (2002) [11C]RN5: a new agent for the in vivo imaging of myocardial α1-adrenoceptors. Eur J Pharmacol 453:231–238PubMedGoogle Scholar
  208. Mathias CJ, Hubers D, Low PS, Green MA (2000) Synthesis of [99mTc]DTPA-folate and its evaluation as a folate–receptor–targeted radiopharmaceutical. Bioconjugate Chem 11:253–257Google Scholar
  209. Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Lewis JS, Yang Z–F, Waters DJ, Snyder PW, Low PS, Welch MJ, Green MA (2003) Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl Med Biol 30:725–731Google Scholar
  210. Mathis CA, Simpson NR, Mahmood K, Kinahan PE, Mintun MA (1994) [11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. Life Sci 55: 403–407Google Scholar
  211. Matsumura K, Uno Y, Scheffel U, Wilson AA, Dannals RF, Wagner HN Jr (1991) In vitro and in vivo characterization of 4-[125I]iododexetimide binding to muscarinic cholinergic receptors in the rat heart. J Nucl Med 32:76–80PubMedGoogle Scholar
  212. Mazière B, Halldin C (2004) PET tracers for brain scanning. In: Ell PJ, Gambhir SS (eds) nuclear medicine in clinical diagnosis and treatment. Churchill Livingstone, Edinburgh, pp 1295–1329Google Scholar
  213. Maziere M, Comar D, Godot JM, Collard P, Cepeda C, Naquet R (1981) In vivo characterization of myocardium muscarinic receptors by positron emission tomography. Life Sci 29:2391–2397PubMedGoogle Scholar
  214. Maziere M, Hantraye P, Prenant C, Sastre J, Comar D (1984) Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4] benzodiazepine-3-carboxylate (Ro 15-1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot 35:973–976PubMedGoogle Scholar
  215. Mazzi U (2006) Technetium, rhenium and other metals in chemistry and nuclear medicine. SGEditoriali, PadovaGoogle Scholar
  216. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA (2005) Quantitative PET studies of the serotonin transporter in MDMA Users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30:1741–1750PubMedGoogle Scholar
  217. McLeod DG (1993) Antiandrogenic drugs. Cancer 71:1046–1049PubMedGoogle Scholar
  218. McPherson DW, Greenbaum M, Luo H, Beets AL, Knapp FF (2000) Evaluation of Z-(R,R)-IQNP for the potential imaging of m2 mAChR rich regions of the brain and heart. Life Sci 66:885–896PubMedGoogle Scholar
  219. Merlet P, Delforge J, Syrota A, Angevin E, Maziere B, Crouzel C, Valette H, Loisance D, Castaigne A, Rande JL (1993) Positron emission tomography with 11C CGP-12177 to assess β-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 87: 1169–1178PubMedGoogle Scholar
  220. Mertens J, Terriere D, Sipido V, Gommeren W, Janssen PMF, Leysen JE (1994) Radiosynthesis of a new radioiodinated ligand for serotonin-5HT2-receptors, a promising tracer for γ-emission tomography. J Labelled Comp Radiopharm 34:795–806Google Scholar
  221. Mitterhauser M, Wadsak W, Wabnegger L, Mien L–K, Togel S, Langer O, Sieghart W, Viernstein H, Kletter K, Dudczak R (2004) Biological evaluation of 2-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nucl Med Biol 31:291–295Google Scholar
  222. Moerlein SM, Perlmutter JS (1992) Binding of 5-(2-[18F]fluoroethyl)flumazenil to central benzodiazepines receptors measured in living baboon by positron emission tomography. Eur J Pharmacol 218:109–115PubMedGoogle Scholar
  223. Moerlein SM, Parkinson D, Welch MJ (1990) Radiosynthesis of high effective specific-activity [123I]SCH 23982 for dopamine D-1 receptor-based SPECT imaging. Int J Rad Appl Instrum [A] 41:381–385Google Scholar
  224. Moerlein SM, Perlmutter JS, Markham J, Welch MJ (1997) In vivo kinetics of [18F](N-methyl)benperidol: a novel pet tracer for assessment of dopaminergic D2-like receptor binding. J Cereb Blood Flow Metab 17:833–845PubMedGoogle Scholar
  225. Moresco RM, Matarrese M, Soloviev D, Simonelli P, Rigamonti M, Gobbo C, Todde S, Carpinelli A, Galli Kienle M, Fazio F (2000) Synthesis and in vivo evaluation of [11C]ICI 118551 as a putative subtype selective β2-adrenergic radioligand. Int J Pharm 204:101–109PubMedGoogle Scholar
  226. Mori T, Kasamatsu S, Mosdzianowski C, Welch MJ, Yonekura Y, Fujibayashi Y (2006) Automatic synthesis of 16α-[18F]fluoro-17β-estradiol using a cassette-type [18F]fluorodeoxyglucose synthesizer. Nucl Med Biol 33:281–286PubMedGoogle Scholar
  227. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ (1996) Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16α-[18F]fluoro-17β-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2:933–939PubMedGoogle Scholar
  228. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ (2001) metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19:2797–2803PubMedGoogle Scholar
  229. Mukherjee J, Narayanan TK, Christian BT, Shi B, Dunigan KA, Mantil J (2000) In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist 11C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate. Synapse 37:64–70PubMedGoogle Scholar
  230. Mukherjee J, Narayanan TK, Christian BT, Shi B, Yang ZY (2004a) Binding characteristics of high-affinity dopamine D2∕D3 receptor agonists, 11C-PPHT and 11C-ZYY-339 in rodents and imaging in non-human primates by PET. Synapse 54:83–91PubMedGoogle Scholar
  231. Mukherjee J, Shi B, Christian BT, Chattopadhyay S, Narayanan TK (2004b) 11C-Fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2∕D3 receptor PET radiotracer in non-human primate brain. Bioorg Med Chem 12:95–102PubMedGoogle Scholar
  232. Mull ES, Sattigeri VJ, Rodriguez AL, Katzenellenbogen JA (2002) Aryl cyclopentadienyl tricarbonyl rhenium complexes: novel ligands for the estrogen receptor with potential use as estrogen radiopharmaceuticals. Bioorg Med Chem 10:1381–1398PubMedGoogle Scholar
  233. Müller C, Hohn A, Schubiger AP, Schibli R (2006) Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Eur J Nucl Med Mol Imaging 33:1007–1016PubMedGoogle Scholar
  234. Murali D, Flores LG, Roberts AD, Nickles RJ, DeJesus OT (2003) Aromatic -amino acid decarboxylase (AAAD) inhibitors as carcinoid tumor-imaging agents: synthesis of 18F-labeled α-fluoromethyl-6-fluoro-m-tyrosine (FM-6-FmT). Appl Radiat Isot 59:237–243PubMedGoogle Scholar
  235. Murphy LC, Watson PH (2006) Is oestrogen receptor-β a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13:327–334PubMedGoogle Scholar
  236. Nakatsuka I, Saji H, Shiba K, Shimizu H, Okuno M, Yoshitake A, Yokoyama A (1987) In vitro evaluation of radioiodinated butyrophenones as radiotracer for dopamine receptor study. Life Sci 41:1989–1997PubMedGoogle Scholar
  237. Nicolaas P, Verhoeff LG (1999) Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology 147:217–249Google Scholar
  238. Nijkamp FP, Henricks PA (1990) Receptors in airway disease. β-adrenoceptors in lung inflammation. Am Rev Respir Dis 141:S145–S150PubMedGoogle Scholar
  239. Nutt DJ, Malizia AL (2001) New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390–396PubMedGoogle Scholar
  240. Okarvi SM, Jammaz IA (2006) Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother Radiopharm 21:49–60PubMedGoogle Scholar
  241. Osman S, Lundkvist C, Pike VW, Halldin C, McCarron JA, Swahn C-G, Farde L, Ginovart N, Luthra SK, Gunn RN (1998) characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635–Explanation of high signal contrast in PET and an aid to biomathematical modelling. Nucl Med Biol 25:215–223PubMedGoogle Scholar
  242. Owens MJ (1996/1997) Molecular and cellular mechanisms of antidepressant drugs. Depress Anxiety 4:153–159Google Scholar
  243. Palmer AM, Francis PT, Benton JS, Sims NR, Mann DM, Neary D, Snowden JS, Bowen DM (1987) Presynaptic serotonergic dysfunction in patients with Alzheimer’s disease. J Neurochem 48:8–15PubMedGoogle Scholar
  244. Palmieri C, Cheng GJ, Saji S, Zelada–Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA (2002) Estrogen receptor beta in breast cancer. Endocr Relat Cancer 9:1–13PubMedGoogle Scholar
  245. Panwar P, Shrivastava V, Tandon V, Mishra P, Chuttani K, Sharma RK, Chandra R, Mishra AK (2004) 99mTc-tetraethylenepentamine-folate — a new 99mTc-based folate derivative for the detection of folate receptor positive tumors: synthesis and biological evaluation. Cancer Biol Ther 3:995–1001PubMedGoogle Scholar
  246. Parent EE, Dence CS, Sharp TL, Welch MJ, Katzenellenbogen JA (2006a) Synthesis and biological evaluation of a fluorine-18-labeled nonsteroidal androgen receptor antagonist, N-(3-[18F]fluoro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicarboxylic imide. Nucl Med Biol 33:615–624PubMedGoogle Scholar
  247. Parent EE, Jenks C, Sharp T, Welch MJ, Katzenellenbogen JA (2006b) Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide. Nucl Med Biol 33:705–713PubMedGoogle Scholar
  248. Passchier J, van Waarde A (2001) Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system. Eur J Nucl Med 28:119–129Google Scholar
  249. Peremans K, Audenaert K, Hoybergs Y, Otte A, Goethals I, Gielen I, Blankaert P, Vervaet M, Heeringen Cv, Dierckx R (2005) The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with 123I-5-I-R91150 SPECT. Eur J Nucl Med Mol Imaging 32:708–716PubMedGoogle Scholar
  250. Piccini P, Whone A (2004) Functional brain imaging in the differential diagnosis of Parkinson’s disease. Lancet Neurol 3:284–290PubMedGoogle Scholar
  251. Pike VW, McCarron JA, Lammertsma AA, Osman S, Hume SP, Sargent PA, Bench CJ, Cliffe IA, Fletcher A, Grasby PM (1996) Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C] WAY-100635. Eur J Pharmacol 301:R5–R7PubMedGoogle Scholar
  252. Pike VW, Law MP, Osman S, Davenport RJ, Rimoldi O, Giardina D, Camici PG (2000) Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors. Pharm Acta Helv 74:191–200PubMedGoogle Scholar
  253. Pleis JR, Lethbridge CM (2006) Summary health statistics for U.S. adults: National Health Interview Survey, 2005. Vital Health Stat 10:1–153Google Scholar
  254. Plisson C, McConathy J, Martarello L, Malveaux EJ, Camp VM, Williams L, Votaw JR, Goodman MM (2004) Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2-carbomethoxy-3-[4-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter. J Med Chem 47:1122–1135PubMedGoogle Scholar
  255. Pomper MG, Katzenellenbogen JA, Welch MJ, Brodack JW, Mathias CJ (1988) 21-[18F]fluoro-16α-ethyl-19-norprogesterone: synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography. J Med Chem 31:1360–1363PubMedGoogle Scholar
  256. Qing F, Rahman SU, Rhodes CG, Hayes MJ, Sriskandan S, Ind PW, Jones T, Hughes JM (1997) Pulmonary and cardiac β-adrenoceptor density in vivo in asthmatic subjects. Am J Respir Crit Care Med 155:1130–1134PubMedGoogle Scholar
  257. Quinlivan M, Mattner F, Papazian V, Zhou J, Katsifis A, Emond P, Chalon S, Kozikowski A, Guilloteau D, Kassiou M (2003) Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter. Nucl Med Biol 30:741–746PubMedGoogle Scholar
  258. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musachio J, Rothman RB, Tsung-Ping S, Tam SW, Taylor DP (1992) A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 13:85–86PubMedGoogle Scholar
  259. Ravert HT, Scheffel U, Mathews WB, Musachio JL, Dannals RF (2002) [11C]–GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. Nucl Med Biol 29:47–53PubMedGoogle Scholar
  260. Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP (2004) Preclinical evaluation of 99mTc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 45:857–866PubMedGoogle Scholar
  261. Reddy JA, Allagadda VM, Leamon CP (2005) Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr Pharm Biotechnol 6:131–150PubMedGoogle Scholar
  262. Rijks LJ, Boer GJ, Endert E, de Bruin K, van den Bos JC, van Doremalen PA, Schoonen WG, Janssen AG, van Royen EA (1996) The stereoisomers of 17α-[123I]iodovinyloestradiol and its 11α-methoxy derivative evaluated for their oestrogen receptor binding in human MCF-7 cells and rat uterus, and their distribution in immature rats. Eur J Nucl Med Mol Imaging 23:295–307Google Scholar
  263. Rijks LJM, van den Bos JC, van Doremalen PAPM, Boer GJ, de Bruin K, Janssen AGM, van Royen EA (1998) New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 2: In vivo pharmacological characterization. Nucl Med Biol 25:791–798PubMedGoogle Scholar
  264. Rossin R, Pan D, Qi K, Turner JL, Sun X, Wooley KL, Welch MJ (2005) 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 46:1210–1218PubMedGoogle Scholar
  265. Rowland DJ, Tu Z, Xu J, Ponde D, Mach RH, Welch MJ (2006) Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled σ2-receptor ligands. J Nucl Med 47:1041–1048PubMedGoogle Scholar
  266. Ryzhikov NN, Seneca N, Krasikova RN, Gomzina NA, Shchukin E, Fedorova OS, Vassiliev DA, Gulyas B, Hall H, Savic I, Halldin C (2005) Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol 32:109–116PubMedGoogle Scholar
  267. Saigal N, Pichika R, Easwaramoorthy B, Collins D, Christian BT, Shi B, Narayanan TK, Potkin SG, Mukherjee J (2006) Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. J Nucl Med 47:1697–1706PubMedGoogle Scholar
  268. Samnick S, Remy N, Ametamey S, Bader JB, Brandau W, Kirsch C-M (1998) 123I-MSP and F[11C]MSP: new selective 5-HT2A receptor radiopharmaceuticals for in vivo studies of neuronal 5-HT2 serotonin receptors. Synthesis, in vitro binding study with unlabelled analogues and preliminary in vivo evaluation in mice. Life Sci 63:2001–2013PubMedGoogle Scholar
  269. Sanchez-Pernaute R, Brownell AL, Isacson O (2002) functional imaging of the dopamine system: in vivo evaluation of dopamine deficiency and restoration. Neurotoxicology 23:469–478PubMedGoogle Scholar
  270. Santos AF, Huang H, Tindall DJ (2004) The androgen receptor: a potential target for therapy of prostate cancer. Steroids 69:79–85PubMedGoogle Scholar
  271. Schafers MA, Wichter T, Schafers KP, Rahman S, Rhodes CG, Lammertsma AA, Lerch H, Knickmeier M, Hermansen F, Schober O, Camici PG, Breithardt G (2001) Pulmonary β-adrenoceptor density in arrhythmogenic right ventricular cardiomyopathy and idiopathic tachycardia. Basic Res Cardiol 96:91–97PubMedGoogle Scholar
  272. Schins A, Van Kroonenburgh M, Van Laere K, D’Haenen H, Lousberg R, Crijns H, Eersels J, Honig A (2005) Increased cerebral serotonin-2A receptor binding in depressed patients with myocardial infarction. Psychiatry Res 139:155–163PubMedGoogle Scholar
  273. Schirrmacher E, Schirrmacher R, Thews O, Dillenburg W, Helisch A, Wessler I, Buhl R, Hohnemann S, Buchholz H–G, Bartenstein P, Machulla H-J, Rosch F (2003) Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([18F]FEFE) for the in vivo visualisation and quantification of the β2-adrenergic receptor status in lung. Bioorg Med Chem Lett 13: 2687–2692Google Scholar
  274. Seimbille Y, Rousseau J, Benard F, Morin C, Ali H, Avvakumov G, Hammond GL, van Lier JE (2002) 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 67:765–775PubMedGoogle Scholar
  275. Seimbille Y, Benard F, Rousseau J, Pepin E, Aliaga A, Tessier G, van Lier JE (2004) Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16α-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol 31:691–698PubMedGoogle Scholar
  276. Seo JW, Comninos JS, Chi DY, Kim DW, Carlson KE, Katzenellenbogen JA (2006) Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem 49:2496–2511PubMedGoogle Scholar
  277. Shiue CY, Welch MJ (2004) Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose. Radiol Clin North Am 42:1033–1053PubMedGoogle Scholar
  278. Shiue CY, Bai LQ, Teng RR, Arnett CD, Dewey SL, Wolf AP, McPherson DW, Fowler JS, Logan J, Holland MJ (1991) A comparison of the brain uptake of N-(cyclopropyl[11C]methyl)norbuprenorphine ([11C]buprenorphine) and N-(cyclopropyl[11C]methyl)nordiprenorphine ([11C]diprenorphine) in baboon using PET. Int J Rad Appl Instrum B 18:281–288PubMedGoogle Scholar
  279. Shiue CY, Shiue GG, Zhang SX, Wilder S, Greenberg JH, Benard F, Wortman JA, Alavi AA (1997) N-(N-Benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: a potential ligand for PET imaging of σ receptors. Nucl Med Biol 24:671–676PubMedGoogle Scholar
  280. Shiue CY, Pleus RC, Shiue GG, Rysavy JA, Sunderland JJ, Cornish KG, Young SD, Bylund DB (1998) Synthesis and biological evaluation of [11C]MK-912 as an α2-adrenergic receptor radioligand for PET studies. Nucl Med Biol 25:127–133PubMedGoogle Scholar
  281. Sibley DR, Monsma JFJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69PubMedGoogle Scholar
  282. Sibley DR, De Lean A, Creese I (1982) Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem 257:6351–6361PubMedGoogle Scholar
  283. Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, Burt RW, Ellis PR, Mathias CJ, Green MA, Gershenson DM (2003) Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 44:700–707PubMedGoogle Scholar
  284. Skaddan MB, Wust FR, Jonson S, Syhre R, Welch MJ, Spies H, Katzenellenbogen JA (2000) Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7α-substituted estradiol complexes. Nucl Med Biol 27:269–278PubMedGoogle Scholar
  285. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ (2004) antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients:a phase iii trial (CALGB 9583). J Clin Oncol 22:1025–1033PubMedGoogle Scholar
  286. Smith JS, Zubieta JK, Price JC, Flesher JE, Madar I, Lever JR, Kinter CM, Dannals RF, Frost JJ (1999) Quantification of δ-opioid receptors in human brain with N1-([11C]Methyl) naltrindole and positron emission tomography. J Cereb Blood Flow Metab 19:956–966PubMedGoogle Scholar
  287. Sobrio F, Amokhtari M, Gourand F, Dhilly M, Dauphin F, Barre L (2000) Radiosynthesis of [18F]Lu29-024: a potential PET ligand for brain imaging of the serotonergic 5-HT2 receptor. Bioorg Med Chem 8:2511–2518PubMedGoogle Scholar
  288. Soloviev DV, Matarrese M, Moresco RM, Todde S, Bonasera TA, Sudati F, Simonelli P, Magni F, Colombo D, Carpinelli A, Galli Kienle M, Fazio F (2001) Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[11C]bisoprolol, a putative β1-selective adrenoceptor radioligand. Neurochem Int 38:169–180PubMedGoogle Scholar
  289. Sprenger T, Berthele A, Platzer S, Boecker H, Tolle TR (2005) What to learn from in vivo opioidergic brain imaging? Eur J Pain 9:117–121PubMedGoogle Scholar
  290. Stamatakis EA, Hetherington MM (2003) Neuroimaging in eating disorders. Nutr Neurosci 6: 325–334PubMedGoogle Scholar
  291. Starke K (1981) α-Adrenoceptor subclassification. Rev Physiol Biochem Pharmacol 88: 199–236PubMedGoogle Scholar
  292. Stockmeier CA (2003) Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res 37: 357–373PubMedGoogle Scholar
  293. Sucharov CC (2007) β-adrenergic pathways in human heart failure. Expert Rev Cardiovasc Ther 5:119–124PubMedGoogle Scholar
  294. Suehiro M, Dannals RF, Scheffel U, Stathis M, Wilson AA, Ravert HT, Villemagne VL, Sanchez-Roa PM, Wagner HN Jr, (1990) In vivo labeling of the dopamine D2 receptor with N-11C-methyl-benperidol. J Nucl Med 31:2015–2021PubMedGoogle Scholar
  295. Sun C, Sze R, Zhang M (2006) Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 78:550–557PubMedGoogle Scholar
  296. Takahashi N, Yang DJ, Kohanim S, Oh CS, Yu DF, Azhdarinia A, Kurihara H, Zhang X, Chang JY, Edmund KE (2008) Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL. Eur J Nucl Med Mol Imaging (in press)Google Scholar
  297. Takamatsu S, Furukawa T, Mori T, Yonekura Y, Fujibayashi Y (2005) Noninvasive imaging of transplanted living functional cells transfected with a reporter estrogen receptor gene. Nucl Med Biol 32:821–829PubMedGoogle Scholar
  298. Talbot PS, Laruelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503–511PubMedGoogle Scholar
  299. Talbot PS, Narendran R, Butelman ER, Huang Y, Ngo K, Slifstein M, Martinez D, Laruelle M, Hwang DR (2005) 11C-GR103545, a radiotracer for imaging κ-opioid receptors in vivo with PET: synthesis and evaluation in baboons. J Nucl Med 46:484–494PubMedGoogle Scholar
  300. Tan PZ, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS, Innis RB (1999) Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. Nucl Med Biol 26:601–608PubMedGoogle Scholar
  301. Tewson TJ, Stekhova S, Kinsey B, Chen L, Wiens L, Barber R (1999) Synthesis and biodistribution of R- and S-isomers of [18F]-fluoropropranolol, a lipophilic ligand for the β-adrenergic receptor. Nucl Med Biol 26:891–896PubMedGoogle Scholar
  302. Tipre DN, Zoghbi SS, Liow JS, Green MV, Seidel J, Ichise M, Innis RB, Pike VW (2006) PET Imaging of brain 5-HT1A receptors in rat in vivo with 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole. J Nucl Med 47:345–353PubMedGoogle Scholar
  303. Trump DP, Mathias CJ, Yang Z, Low PS, Marmion M, Green MA (2002) Synthesis and evaluation of 99mTc(CO)3-DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol 29:569–573PubMedGoogle Scholar
  304. Tsoukalas C, Pirmettis I, Patsis G, Pelecanou M, Bodo K, Raptopoulou CP, Terzis A, Papadopoulos M, Chiotellis E (2003) Novel oxorhenium and oxotechnetium MO(NS)(S)2 complexes in the development of 5-HT1A receptor imaging agents. J Inorg Biochem 93: 213–220PubMedGoogle Scholar
  305. Tu Z, Dence CS, Ponde DE, Jones L, Wheeler KT, Welch MJ, Mach RH (2005) Carbon-11 labeled σ2 receptor ligands for imaging breast cancer. Nucl Med Biol 32:423–430PubMedGoogle Scholar
  306. Turner MR, Cagnin A, Turkheimer FE, Miller CCJ, Shaw CE, Brooks DJ, Leigh PN, Banati RB (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15:601–609PubMedGoogle Scholar
  307. Tyacke RJ, Robinson ESJ, Schnabel R, Lewis JW, Husbands SM, Nutt DJ, Hudson AL (2002) N1-fluoroethyl-naltrindole (BU97001) and N1-fluoroethyl-(14-formylamino)-naltrindole (BU97018) potential δ-opioid receptor PET ligands. Nucl Med Biol 29:455–462PubMedGoogle Scholar
  308. Ueki J, Rhodes CJ, Hughes JM, De–Silva R, Lefroy DC, Ind PW, Qing F, Brady F, Luthra SK, Steel CJ (1993) In vivo quantification of pulmonary β-adrenoceptor density in humans with (S)-[11C]CGP–12177 and PET. J Appl Physiol 75:559–565Google Scholar
  309. Valette H, Dolle F, Guenther I, Demphel S, Rasetti C, Hinnen F, Fuseau C, Crouzel C (1999) Preliminary evaluation of 2-[4-[3-(tert-Butylamino)-2-hydroxypropoxy]phenyl]-3-methyl-6-methoxy-4(3H)-quinazolinone ([ + ∕−]HX-CH 44) as a selective β1-adrenoceptor ligand for PET. Nucl Med Biol 26:105–109PubMedGoogle Scholar
  310. Valk PE, Bailey DL, Townsend DW, Maisey MN (2003) Positron emission tomography: basic science and clinical practice. Springer, LondonGoogle Scholar
  311. van den Bos JC, Rijks LJM, van Doremalen PAPM, de Bruin K, Janssen AGM, van Royen EA (1998) New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 1: synthesis and in vitro pharmacological characterization. Nucl Med Biol 25:781–789PubMedGoogle Scholar
  312. Van Den Bossche B, Van de Wiele C (2004) receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 22:3593–3607Google Scholar
  313. Van der Mey M, Windhorst AD, Klok RP, Herscheid JDM, Kennis LE, Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE (2006) Synthesis and biodistribution of [11C]R107474, a new radiolabeled α2-adrenoceptor antagonist. Bioorg Med Chem 14:4526–4534PubMedGoogle Scholar
  314. van Waarde A, Visser TJ, Elsinga PH, de Jong BM, van der Mark TW, Kraan J, Ensing K, Pruim J, Willemsen ATM, Brodde O-E, Visser GM, Paans AMJ, Vaalburg W (1997) Imaging β-adrenoceptors in the human brain with (S)-l-[18F]fluorocarazolol. J Nucl Med 38:934–939PubMedGoogle Scholar
  315. van Waarde A, Elsinga PH, Doze P, Heldoorn M, Jaeggi KA, Vaalburg W (1998) A novel β-adrenoceptor ligand for positron emission tomography: evaluation in experimental animals. Eur J Pharmacol 343:289–296PubMedGoogle Scholar
  316. van Waarde A, Buursma AR, Hospers GAP, Kawamura K, Kobayashi T, Ishii K, Oda K, Ishiwata K, Vaalburg W, Elsinga PH (2004) Tumor imaging with 2 σ-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med 45:1939–1945PubMedGoogle Scholar
  317. van Waarde A, Maas B, Doze P, Slart RH, Frijlink HW, Vaalburg W, Elsinga PH (2005) positron emission tomography studies of human airways using an inhaled β-adrenoceptor antagonist, S-11C-CGP 12388. Chest 128:3020–3027PubMedGoogle Scholar
  318. van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH (2006) early response of σ-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med 47:1538–1545PubMedGoogle Scholar
  319. VanBrocklin HF, Blagoev M, Hoepping A, O’Neil JP, Klose M, Schubiger PA, Ametamey S (2004) A new precursor for the preparation of 6-[18F]fluoro-m-tyrosine ([18F]FMT): efficient synthesis and comparison of radiolabeling. Appl Radiat Isot 61:1289–1294PubMedGoogle Scholar
  320. Vandecapelle M, De Vos F, Vermeirsch H, De Ley G, Audenaert K, Leysen D, Dierckx RA, Slegers G (2001) In vivo evaluation of 4-[123I]iodo-N-{2-[4-(6-trifluoromethyl-2-pyridinyl)-1-piperazinyl]ethyl}benzamide, a potential SPECT radioligand for the 5-HT1A receptor. Nucl Med Biol 28:639–643PubMedGoogle Scholar
  321. Verhagen A, Luurtsema G, Pesser JW, de Groot TJ, Wouda S, Oosterhuis JW, Vaalburg W (1991) Preclinical evaluation of a positron emitting progestin ([18F]fluoro-16α-methyl-19-norprogesterone) for imaging progesterone receptor positive tumours with positron emission tomography. Cancer Lett 59:125–132PubMedGoogle Scholar
  322. Verhagen A, Studeny M, Luurtsema G, Visser GM, De Goeij CCJ, Sluyser M, Nieweg OE, van der Ploeg E, Go KG, Vaalburg W (1994) Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16α-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol 21:941–952PubMedGoogle Scholar
  323. Versijpt J, Van Laere KJ, Dumont F, Decoo D, Vandecapelle M, Santens P, Goethals I, Audenaert K, Slegers G, Dierckx RA, Korf J (2003a) Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings. Neurobiol Aging 24:553–561PubMedGoogle Scholar
  324. Versijpt JJ, Dumont F, van Laere KJ, Decoo D, Santens P, Audenaert K, Achten E, Slegers G, Dierckx RA, Korf J (2003b) Assessment of neuroinflammation and microglial activation in Alzheimer’s disease with radiolabelled PK11195 and single photon emission computed tomography. Eur Neurol 50:39–47PubMedGoogle Scholar
  325. Vilner BJ, John CS, Bowen WD (1995) σ1 and σ2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55:408–413PubMedGoogle Scholar
  326. Visser TJ, van Waarde A, Jansen TJH, Visser GM, van der Mark TW, Kraan J, Ensing K, Vaalburg W (1997a) Stereoselective synthesis and biodistribution of potent [11C]-labeled antagonists for positron emission tomography imaging of muscarinic receptors in the airways. J Med Chem 40:117–124PubMedGoogle Scholar
  327. Visser TJ, van Waarde A, van der Mark TW, Kraan J, Elsinga PH, Pruim J, Ensing K, Jansen T, Willemsen ATM, Franssen EJF, Visser GM, Paans AMJ, Vaalburg W (1997b) Characterization of pulmonary and myocardial β–adrenoceptors with S-1-[fluorine-18]fluorocarazolol. J Nucl Med 38:169–174PubMedGoogle Scholar
  328. Visser TJ, van Waarde A, Doze P, Elsinga PH, van der Mark TW, Kraan J, Ensing K, Vaalburg W (1998) Characterisation of β2–adrenoceptors, using the agonist [11C]formoterol and positron emission tomography. Eur J Pharmacol 361:35–41PubMedGoogle Scholar
  329. Visser TJ, van Waarde A, van der Mark TW, Kraan J, Ensing K, Willemsen ATM, Elsinga PH, Vaalburg W (1999) Detection of muscarinic receptors in the human lung using PET. J Nucl Med 40:1270–1276PubMedGoogle Scholar
  330. Wagner HN, Jr., Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221:1264–1266PubMedGoogle Scholar
  331. Wagner S, Kopka K, Law MP, Riemann B, Pike VW, Schober O, Schafers M (2004) Synthesis and first in vivo evaluation of new selective high affinity β1-adrenoceptor radioligands for SPECT based on ICI 89,406. Bioorg Med Chem 12:4117–4132PubMedGoogle Scholar
  332. Wang S, Lee RJ, Mathias CJ, Green MA, Low PS (1996) Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjugate Chem 7:56–62Google Scholar
  333. Wang S, Luo J, Lantrip DA, Waters DJ, Mathias CJ, Green MA, Fuchs PL, Low PS (1997) Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chem 8:673–679Google Scholar
  334. Waterhouse RN, Chapman J, Izard B, Donald A, Belbin K, O’Brien JC, Collier TL (1997) Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models. Nucl Med Biol 24:587–593PubMedGoogle Scholar
  335. Waterhouse RN, Stabin MG, Page JG (2003) Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel σ1 receptor radiotracer [18F]FPS. Nucl Med Biol 30:555–563PubMedGoogle Scholar
  336. Wedeking PW, Wager RE, Arunachalam T, Ramalingam K, Linder KE, Ranganathan RS, Nunn AD, Raju N, Tweedle MF (2002) Metal complexes derivatized with folate for use in diagnostic and therapeutic application. US Patent 6221334Google Scholar
  337. Welch MJ, Redvanly CS (2003) Handbook of radiopharmaceuticals: radiochemistry and applications. Wiley, ChichesterGoogle Scholar
  338. Weng YH, Yen TC, Chen MC, Kao PF, Tzen KY, Chen RS, Wey SP, Ting G, Lu CS (2004) sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson’s disease from healthy subjects. J Nucl Med 45:393–401PubMedGoogle Scholar
  339. Westkaemper RB, Glennon RA (2002) Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT2A ligands. Curr Top Med Chem 2:575–598PubMedGoogle Scholar
  340. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH (2000) Sigma-2 receptors as a biomarker of proliferation in solid tumors. Br J Cancer 82:1223–1232PubMedGoogle Scholar
  341. Wichter T, Schafers M, Rhodes CG, Borggrefe M, Lerch H, Lammertsma AA, Hermansen F, Schober O, Breithardt G, Camici PG (2000) Abnormalities of cardiac sympathetic innervation in arrhythmogenic right ventricular cardiomyopathy: quantitative assessment of presynaptic norepinephrine reuptake and postsynaptic β-adrenergic receptor density with positron emission tomography. Circulation 101:1552–1558PubMedGoogle Scholar
  342. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N (2005) Radiosynthesis and evaluation of [11C]-(+)-4–propyl-3,4,4a,5,6,10b-hexahydro-2h-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153–4160PubMedGoogle Scholar
  343. Wong DF, Brasic JR (2001) In vivo imaging in neurotransmitter systems in neuropsychiatry. Clin Neurosc Res 1:35–45Google Scholar
  344. Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, Chan B, Folio T, Scheffel U, Ricaurte GA, Neumeyer JL, Wagner HN Jr, Michael JK (1993) In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse 15:130–142PubMedGoogle Scholar
  345. Wu WL, Burnett DA, Spring R, Greenlee WJ, Smith M, Favreau L, Fawzi A, Zhang H, Lachowicz JE (2005) Dopamine D1∕D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1∕D5 antagonists. J Med Chem 48:680–693PubMedGoogle Scholar
  346. Yamada S, Ishima T, Tomita T, Hayashi M, Okada T, Hayashi E (1984) Alterations in cardiac α and β adrenoceptors during the development of spontaneous hypertension. J Pharmacol Exp Ther 228:454–460PubMedGoogle Scholar
  347. Yamada S, Ohkura T, Uchida S, Inabe K, Iwatani Y, Kimura R, Hoshino T, Kaburagi T (1996) A sustained increase in β-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy. Life Sci 58:1737–1744PubMedGoogle Scholar
  348. Yamaguchi I, Kopin IJ (1980) Differential inhibition of α1 and α2 adrenoceptor-mediated pressor responses in pithed rats. J Pharmacol Exp Ther 214:275–281PubMedGoogle Scholar
  349. Yang ZY, Perry B, Mukherjee J (1996) Fluorinated benzazepines: 1. Synthesis, radiosynthesis and biological evaluation of a series of substituted benzazepines as potential radiotracers for positron emission tomographic studies of dopamine D-1 receptors. Nucl Med Biol 23:793–805PubMedGoogle Scholar
  350. Yoo J, Dence CS, Sharp TL, Katzenellenbogen JA, Welch MJ (2005) Synthesis of an estrogen receptor-selective radioligand: 5-[18F]fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16-[18F]fluoro-17-estradiol. J Med Chem 48:6366–6378PubMedGoogle Scholar
  351. Yoshida Y, Kurokawa T, Sawamura Y, Shinagawa A, Okazawa H, Fujibayashi Y, Kotsuji F (2007) The positron emission tomography with F18 17β-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol 104:764-766PubMedGoogle Scholar
  352. Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, Squire O, Morris M, Scher H, McCarthy T, Welch M, Larson SM, Humm JL (2004) PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 45:1966–1971PubMedGoogle Scholar
  353. Zessin J, Deuther-Conrad W, Kretzschmar M, Wust F, Pawelke B, Brust P, Steinbach J, Bergmann R (2006) [11C]SMe-ADAM, an imaging agent for the brain serotonin transporter: synthesis, pharmacological characterization and microPET studies in rats. Nucl Med Biol 33:53–63PubMedGoogle Scholar
  354. Zhang MR, Kida T, Noguchi J, Furutsuka K, Maeda J, Suhara T, Suzuki K (2003a) [11C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. Nucl Med Biol 30:513–519PubMedGoogle Scholar
  355. Zhang MR, Maeda J, Furutsuka K, Yoshida Y, Ogawa M, Suhara T, Suzuki K (2003b) [18F]FMDAA1106 and [18F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR). Bioorg Med Chem Lett 13:201–204PubMedGoogle Scholar
  356. Zhu Z, Guo N, Narendran R, Erritzoe D, Ekelund J, Hwang DR, Bae SA, Laruelle M, Huang Y (2004) The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. Nucl Med Biol 31:983–994PubMedGoogle Scholar
  357. Zisterer DM, Williams DC (1997) Peripheral-type benzodiazepine receptors. Gen Pharmacol 29:305–314PubMedGoogle Scholar
  358. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ (1996) Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2:1225–1229PubMedGoogle Scholar
  359. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS (2001) Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293:311–315PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Aviv Hagooly
    • 1
  • Raffaella Rossin
    • 1
  • Michael J. Welch
    • 1
    Email author
  1. 1.Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. Louis

Personalised recommendations